Alain Moussy, Co-Founder and CEO, AB Science has applied their lead compound Masitinib to target mast cells and macrophage, also known when presenting with CNS as microglia, from the innate immune system to treat Lou Gehrig's disease, multiple sclerosis, Alzheimer's disease, tumors, and pancreatic cancer.  Now AB Science is turning their attention to fighting the cytokine storm in COVID-19 patients by targeting and blocking mast cells and macrophages which are known to contribute to the inflammation. #masitinib #PancreaticCancer #COVID19 #Alzheimers AB-Science.com Download the transcript here